The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
News
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an…
A signaling molecule released by blood vessel cells prompts cancer cells to grow and become resistant to treatment in glioblastoma, an aggressive type of…
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of ovarian cancer cells in cell…
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
Treatment with certepetide in combination with standard therapies led to stable disease in most people with a type of pancreatic cancer known as…
